SCHEMBL22798285

SCHEMBL22798285

Cc1cc(C(=O)NCCOc2ccc(C(F)(F)F)cc2F)cc(NC(=O)C(C)C)n1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.66
KMT2A Q03164 3/20 0.44
RAB9A P51151 1/20 0.44
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
HTT P42858 2/20 0.40
MAPT P10636 2/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
PPARD Q03181 6/20 0.39
PPARA Q07869 5/20 0.39
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
GSK3B P49841 1/20 0.39
PPARG P37231 2/20 0.37
TRPV1 Q8NER1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22797803 0.93 SCN9A (0.68) SCN9AKMT2ARAB9AKDM4EALDH1A1
SCHEMBL30449593 0.93 SCN9A (0.68) SCN9AKMT2ARAB9AKDM4EALDH1A1
SCHEMBL22797788 0.90 SCN9A (0.75) SCN9AMRGPRX4SMN1; SMN2
SCHEMBL20595207 0.90 SCN9A (0.65) SCN9AKMT2ARAB9AKDM4EALDH1A1
SCHEMBL30450908 0.90 SCN9A (0.65) SCN9AKMT2ARAB9AKDM4EALDH1A1
SCHEMBL22797915 0.90 SCN9A (0.53) SCN9AKMT2ARAB9AKDM4EALDH1A1
SCHEMBL22797766 0.89 SCN9A (0.73) SCN9AKMT2AKDM4EALDH1A1HPGD
SCHEMBL22798288 0.88 SCN9A (0.51) SCN9AKMT2ARAB9AKDM4EALDH1A1
SCHEMBL22797762 0.87 SCN9A (0.67) SCN9AKMT2ARAB9AKDM4EALDH1A1
SCHEMBL22798332 0.87 SCN9A (0.50) SCN9AKMT2ARAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN claimed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP claimed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN claimed
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN disclosed
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2021-10-26 US disclosed
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2021-10-26 US disclosed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP disclosed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers SCN8A, SCN7A, SCN1A SCN9A 9/4885KMT2A 1799/4885RAB9A 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.